CAMBRIDGE, Mass. & CORALVILLE, Iowa--(BUSINESS WIRE)--Feb. 28, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Integrated DNA Technologies, Inc. (IDT), the largest supplier of custom nucleic acids in the U.S., announced today that Alnylam has granted IDT a non-exclusive license to provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers small interfering RNAs (siRNAs) and their use to mediate RNAi in mammalian cells.
